Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-771 in Japanese adults with CIDP or MMN
jRCT2051210110Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2021
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of immunoglobulin g + hyaluronidase, immune globulin 10% and hyaluronidase in chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN) (2 cohorts), sponsored by Takeda. Primary endpoints: Percentage of participants with CIDP who experienced relapse in Epoch 1 and Change in maximum grip strength in the more affected hand in Epoch 1 for participants with MMN. Started Dec 2021; status: completed.
02
Drugs
immunoglobulin g + hyaluronidaseimmune globulin 10%hyaluronidase
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on jRCT2051210110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210110.